Travere Therapeutics

Travere Therapeutics TVTX Stock

$49.19   -2.089974%
Add to favorites
Market Cap
$4.72B
LOW - HIGH [24H]
$48.78 - $51.08
VOLUME [24H]
$295.06K
P/E Ratio
0
Earnings per share
-$1.67
ISIN
US89422G1076
Price   Prediction

Travere Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Travere Therapeutics (TVTX) stock price today is 49.19 USD on Tech Market Middle (-2.09% on the day). Updated .

Travere Therapeutics TVTX Financial and Trading Overview

Travere Therapeutics stock price 49.19 USD
Previous Close 49.7 USD
Open 49.5 USD
Bid 47.37 USD x 200
Ask 78.79 USD x 200
Day's Range 48.25 - 51.18 USD
52 Week Range 22.59 - 68.73 USD
Volume 1.4M USD
Avg. Volume 1.82M USD
Market Cap 4.91B USD
Beta (5Y Monthly) 1.118
PE Ratio (TTM) N/A
EPS (TTM) -1.67 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 73.43 USD

TVTX Valuation Measures

Enterprise Value 5.05B USD
Trailing P/E N/A
Forward P/E 9.432395
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 7.534474
Price/Book (mrq) 216.52542
Enterprise Value/Revenue 7.756
Enterprise Value/EBITDA 155.835

Trading Information

Travere Therapeutics Stock Price History

Beta (5Y Monthly) 1.118
52-Week Change 44.22%
S&P500 52-Week Change 10.51%
52 Week High 68.73 USD
52 Week Low 22.59 USD
50-Day Moving Average 55.32 USD
200-Day Moving Average 47.87 USD

TVTX Share Statistics

Avg. Volume (3 month) 1.82M USD
Avg. Daily Volume (10-Days) 1.47M USD
Shares Outstanding 95.99M
Float 94.95M
Short Ratio 4.65
% Held by Insiders 0.68%
% Held by Institutions 118.99%
Shares Short 9.56M
Short % of Float 12.90%
Short % of Shares Outstanding 9.95%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -18.66%
Operating Margin (ttm) -3.13%
Gross Margin 61.06%
EBITDA Margin 4.97%

Management Effectiveness

Return on Assets (ttm) -1.83%
Return on Equity (ttm) -321.21%

Income Statement

Revenue (ttm) 651.03M USD
Revenue Per Share (ttm) 7.03 USD
Quarterly Revenue Growth (yoy) 36.19%
Gross Profit (ttm) 397.56M USD
EBITDA 32.4M USD
Net Income Avi to Common (ttm) -154422000 USD
Diluted EPS (ttm) -1.67
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 471.82M USD
Total Cash Per Share (mrq) 4.92 USD
Total Debt (mrq) 616.16M USD
Total Debt/Equity (mrq) 2728.28 USD
Current Ratio (mrq) 3.003
Book Value Per Share (mrq) 0.236

Cash Flow Statement

Operating Cash Flow (ttm) 176.59M USD
Levered Free Cash Flow (ttm) -64789248 USD

Profile of Travere Therapeutics

Country United States
State CA
City San Diego
Address 3611 Valley Centre Drive
ZIP 92130
Phone 888 969 7879
Website https://www.travere.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 497

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Q&A For Travere Therapeutics Stock

What is a current TVTX stock price?

Travere Therapeutics TVTX stock price today per share is 49.19 USD.

How to purchase Travere Therapeutics stock?

You can buy TVTX shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Travere Therapeutics?

The stock symbol or ticker of Travere Therapeutics is TVTX.

Which industry does the Travere Therapeutics company belong to?

The Travere Therapeutics industry is Biotechnology.

How many shares does Travere Therapeutics have in circulation?

The max supply of Travere Therapeutics shares is 95.99M.

What is Travere Therapeutics Price to Earnings Ratio (PE Ratio)?

Travere Therapeutics PE Ratio is now.

What was Travere Therapeutics earnings per share over the trailing 12 months (TTM)?

Travere Therapeutics EPS is -1.67 USD over the trailing 12 months.

Which sector does the Travere Therapeutics company belong to?

The Travere Therapeutics sector is Healthcare.

Travere Therapeutics TVTX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24201.34 USD —
-0.94
4.68B USD — 24005.47 USD — 24939.62 USD — — 4.68B USD —
us US Tech Health Care IXHC US 1317.49 USD —
-0.52
— — 1309.03 USD — 1333.62 USD — — — —
us US Tech Global Market Composite NQGM US 1835.64 USD —
-0.18
— — 1820.49 USD — 1866.97 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 2906.69 USD —
-1.16
— — 2885.86 USD — 2954.75 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3605.34 USD —
-0.97
— — 3577.02 USD — 3690.74 USD — — — —
us US Tech Biotechnology NBI US 6965.89 USD —
-0.08
— — 6905.76 USD — 7033.67 USD — — — —
$2.17T
Total marketcap
$71.79B
Total volume
BTC 58.07%   •   ETH 9.95%
Dominance
Select currency